Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report-Reference-Cited by-同舟云学术

Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report

Published:2019-08-14 Issue:22 Volume:125 Page:4033-4042
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Wu Jessica¹,Chen Yanjun¹,Hageman Lindsey¹,Francisco Liton¹,Ness Emily C.¹,Parman Mariel¹,Kung Michelle¹,Watson James A.¹,Weisdorf Daniel J.²,Snyder David S.³,McGlave Philip B.²,Forman Stephen J.⁴,Arora Mukta⁵,Armenian Saro H.⁶^ORCID,Bhatia Ravi⁷,Bhatia Smita¹⁸^ORCID

Affiliation:

1. Institute for Cancer Outcomes and Survivorship University of Alabama at Birmingham Birmingham Alabama

2. Department of Medicine University of Minnesota Minneapolis Minnesota

3. Hematology/Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte California

4. Department of Medicine City of Hope National Medical Center Duarte California

5. Hematology‐Oncology and Blood and Marrow Transplantation University of Minnesota Minneapolis Minnesota

6. Department of Social Sciences and Pediatrics City of Hope National Medical Center Duarte California

7. Division of Hematology and Oncology University of Alabama at Birmingham Birmingham Alabama

8. Department of Pediatrics, School of Medicine University of Alabama at Birmingham Birmingham Alabama

Funder

Leukemia and Lymphoma Society

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32443

Reference20 articles.

1. Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

2. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

3. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease

4. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

5. Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis;Bone Marrow Transplantation;2023-02-27

2. Patient-reported long-term outcome following allogeneic hematopoietic stem cell transplantation in pediatric chronic myeloid leukemia;Frontiers in Oncology;2022-09-29